Samuel Q. Li

MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.

E. Kolaczyk, J. Khan, Jun S. Wei, 2016, Cancer letters.

Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)

J. Khan, Jun S. Wei, Young K. Song, 2013, PloS one.

Massively Parallel Sequencing Reveals an Accumulation of De Novo Mutations and an Activating Mutation of LPAR1 in a Patient with Metastatic Neuroblastoma

J. Khan, Jun S. Wei, P. Johansson, 2013, PloS one.

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Mindy I. Davis, Hongmao Sun, M. Shen, 2013, Bioorganic & medicinal chemistry letters.

Abstract 652: Development and characterization of anti-FGFR4 monoclonal antibodies as therapeutic agents for human rhabdomyosarcoma

D. Dimitrov, J. Maris, R. Orentas, 2014 .